SIZE XSSIZE SMSIZE MDSIZE LG

Updates from American Society of Hematology (ASH) Webinar

Orignially presented: March 8, 2018

Credits: 1 hour BCOP and/or 1 hour ACPE
BCOP credits are available to earn until September 4, 2018

Individual webinar pricing: $40 (member) / $70 (non-member)
This may also be purchased as part of the 2018 BCOP Webinar Bundle.

Purchase Now

HOPA is pleased to present the first of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.

Learning Objective

  • Identify therapeutic strategies poised to impact clinical management of patients with hematologic malignancies based on information presented at the American Society of Hematology (ASH) 59th Annual Meeting.
  • Interpret results and conclusions from key abstracts presented at the ASH 59th Annual Meeting.
  • Select an appropriate treatment plan for patients with various hematologic malignancies based on data presented at the ASH 59th Annual Meeting.

Speaker

Kelly Valla resized

Dr. Kelly Valla, PharmD BCOP

Dr. Kelly Valla earned her doctorate in pharmacy from the University of Illinois at Chicago, where she stayed on to complete her PGY1 Pharmacy Practice and PGY2 Oncology Pharmacy residency training. Following residency, she transitioned into her current role as a clinical pharmacy specialist in hematology/oncology and bone marrow transplantation at Emory University Hospital and the Winship Cancer Institute in Atlanta, Georgia. She also earned designation as a Board Certified Oncology Pharmacist.

In her current role, Dr. Valla practices in both the inpatient and ambulatory care settings where she actively participates in the day-to-day pharmacotherapy of patients with many hematologic malignancies and those undergoing hematopoietic cell transplantation. Additionally, she is active in many institutional committees including the Lymphoma Working Group for clinical trials, the Clinical and Translational Research Committee, the Chemotherapy Quality and Safety Committee, as well as teaching students and both PGY1 and PGY2 residents. Dr. Valla remains active in the American Society for Blood and Marrow Transplantation (ASBMT) where she is currently the Past-Chair of the Education Working Committee within the ASBMT Pharmacy Special Interest Group and is concurrently serving on the Hematology/Oncology Pharmacy Association (HOPA) BCOP Oversight Committee.

Disclosure: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-001-H04-P.

Activity Type:

Application

Accreditation Statement:

logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by September 4, 2018.

education speaker bpslogoThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by September 4, 2018.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

Register Now

xs
sm
md
lg